Femoxetine

Femoxetine
Clinical data
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	In general: uncontrolled;
Pharmacokinetic data
Elimination half-life	7–27 hours
Identifiers
	IUPAC name (3R,4S)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenyl-piperidine;
CAS Number	59859-58-4 ;
PubChem CID	3012003;
ChemSpider	2280941 ;
UNII	8Y719ZLX8C;
ChEMBL	ChEMBL94739 ;
CompTox Dashboard (EPA)	DTXSID70208576 ;
Chemical and physical data
Formula	C20H25NO2
Molar mass	311.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(c1ccc(OC)cc1)C[C@@H]3[C@@H](c2ccccc2)CCN(C)C3;
	InChI InChI=1S/C20H25NO2/c1-21-13-12-20(16-6-4-3-5-7-16)17(14-21)15-23-19-10-8-18(22-2)9-11-19/h3-11,17,20H,12-15H2,1-2H3/t17-,20-/m1/s1 ; Key:OJSFTALXCYKKFQ-YLJYHZDGSA-N ;
	(verify)

Femoxetine (INN; tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition of the company by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, as femoxetine could not be administered as a daily pill.

Quick facts Clinical data, Routes ofadministration ...

Both femoxetine and paroxetine were invented in the 1970s. Jørgen Anders Christensen's name is on the patents^[1]^[2] and Jorgen Buus-Lassen's name is on the pharmacology paper.^[3]

After Ferrosan's acquisition, femoxetine died from neglect.^[4]

In a separate patent, Ferrosan stated that Femoxetine could be used as an appetite suppressant,^[5] using ten times the dosage than for paroxetine, 300 - 400mg daily.

Femoxetine has the same stereochemical properties as Nocaine, another agent with a similar structure claimed to have been synthesized using arecoline as the starting alkaloid.^{[citation needed]}

[1]

[2]

[3]

[4]

[5]

Femoxetine

Analogs

See also

References

Wikiwand - on